Basic Information
ID: ALA4022898
Type: Binding
Description: Corrector activity at CFTR F508del/F508del mutant in primary HBE cells assessed as increase in chloride ion current across apical membrane measured 18 to 24 hrs post compound treatment on basolateral side of cells in presence of channel potentiator GLPG1837 by trans-epithelial current clamp method relative to 3-[(2R,4R)-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]-carbonyl}amino)-7-methoxy-3,4-dihydro-2H-chromen-2-yl]benzoic acid
Format: BAO_0000219
Organism: Homo sapiens
Target: Cystic fibrosis transmembrane conductance regulator(ALA4051)
Document: ALA4020819
Corrector activity at CFTR F508del/F508del mutant in primary HBE cells assessed as increase in chloride ion current across apical membrane measured 18 to 24 hrs post compound treatment on basolateral side of cells in presence of channel potentiator GLPG1837 by trans-epithelial current clamp method relative to 3-[(2R,4R)-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]-carbonyl}amino)-7-methoxy-3,4-dihydro-2H-chromen-2-yl]benzoic acid: 1
Activity Charts
Bioactivity
Activity Types for Assay ALA4022898
max activation
Compound Summary
| Parent Molecular Weight | ALogP | Polar Surface Area |
|---|---|---|
| 523.49 | 5.13 | 5.13 |
| 561.46 | 6.14 | 6.14 |
| 511.45 | 5.26 | 5.26 |
| 523.49 | 5.13 | 5.13 |
| 539.53 | 5.45 | 5.45 |
| 559.47 | 5.72 | 5.72 |
| 479.48 | 4.91 | 4.91 |
| 523.49 | 5.13 | 5.13 |
| 559.47 | 5.72 | 5.72 |